Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Virol ; 78(17): 9190-202, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15308714

RESUMEN

This study evaluated type-specific and cross-reactive neutralizing antibodies induced by immunization with modified surface glycoproteins (SU) of the 63 isolate of caprine arthritis-encephalitis lentivirus (CAEV-63). Epitope mapping of sera from CAEV-infected goats localized immunodominant linear epitopes in the carboxy terminus of SU. Two modified SU (SU-M and SU-T) and wild-type CAEV-63 SU (SU-W) were produced in vaccinia virus and utilized to evaluate the effects of glycosylation or the deletion of immunodominant linear epitopes on neutralizing antibody responses induced by immunization. SU-M contained two N-linked glycosylation sites inserted into the target epitopes by R539S and E542N mutations. SU-T was truncated at 518A, upstream from the target epitopes, by introduction of termination codons at 519Y and 521Y. Six yearling Saanen goats were immunized subcutaneously with 30 microg of SU-W, SU-M, or SU-T in Quil A adjuvant and boosted at 3, 7, and 16 weeks. SU antibody titers determined by indirect enzyme-linked immunosorbent assay demonstrated anamnestic responses after each boost. Wild-type and modified SU-induced type-specific CAEV-63 neutralizing antibodies and cross-reactive neutralizing antibodies against CAEV-Co, a virus isolate closely related to CAEV-63, and CAEV-1g5, an isolate geographically distinct from CAEV-63, were determined. Immunization with SU-T resulted in altered recognition of SU linear epitopes and a 2.8- to 4.6-fold decrease in neutralizing antibody titers against CAEV-63, CAEV-Co, and CAEV-1g5 compared to titers of SU-W-immunized goats. In contrast, immunization with SU-M resulted in reduced recognition of glycosylated epitopes and a 2.4- to 2.7-fold increase in neutralizing antibody titers compared to titers of SU-W-immunized goats. Thus, the glycosylation of linear immunodominant nonneutralization epitopes, but not epitope deletion, is an effective strategy to enhance neutralizing antibody responses by immunization.


Asunto(s)
Anticuerpos Antivirales/inmunología , Virus de la Artritis-Encefalitis Caprina/inmunología , Epítopos Inmunodominantes/química , Epítopos Inmunodominantes/inmunología , Proteínas del Envoltorio Viral/química , Proteínas del Envoltorio Viral/inmunología , Vacunas Virales/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Antivirales/sangre , Especificidad de Anticuerpos/inmunología , Western Blotting , Reacciones Cruzadas/inmunología , Glicosilación , Cabras/inmunología , Cabras/virología , Glicoproteínas de Membrana/química , Glicoproteínas de Membrana/inmunología , Datos de Secuencia Molecular , Pruebas de Neutralización , Vacunas Virales/sangre
2.
Virology ; 306(1): 116-25, 2003 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-12620804

RESUMEN

This study evaluated the efficacy of prime-boost vaccination for immune control of caprine arthritis-encephalitis virus (CAEV), a macrophage tropic lentivirus that causes progressive arthritis in the natural host. Vaccination of Saanen goats with pUC-based plasmid DNA expressing CAEV env induces T helper type 1 (Th1) biased immune responses to vector-encoded surface envelope (SU), and the plasmid-primed Th1 response is expanded following boost with purified SU in Freund's incomplete adjuvant (SU-FIA) (J. C. Beyer et al., 2001, Vaccine 19, 1643-1651). Four goats vaccinated with env expression plasmids and boosted with SU-FIA were challenged intravenously with 1 x 10(4) TCID(50) of CAEV at 428 days after SU-FIA boost and evaluated by immunological, virological, and disease criteria. Controls included two goats primed with pUC18 and eight unvaccinated goats. Goats receiving prime-boost vaccination with CAEV env plasmids and SU-FIA became infected but suppressed postchallenge virus replication, provirus loads in lymph node, and development of arthritis for at least 84 weeks.


Asunto(s)
Virus de la Artritis-Encefalitis Caprina/inmunología , Artritis/prevención & control , Productos del Gen env/inmunología , Glicoproteínas , Infecciones por Lentivirus/prevención & control , Proteínas de la Membrana , Proteínas Virales , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Artritis/virología , Virus de la Artritis-Encefalitis Caprina/patogenicidad , Productos del Gen env/genética , Enfermedades de las Cabras/prevención & control , Enfermedades de las Cabras/virología , Cabras , Inmunización Secundaria , Infecciones por Lentivirus/virología , Ganglios Linfáticos/virología , Plásmidos/genética , Vacunación , Vacunas de ADN/inmunología , Vacunas Virales/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA